Search Result

Results for "

sphingosine biosynthesis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (2) Biochemical Assay Reagents (1) Ceramidase (1) Endogenous Metabolite (1) Isotope-Labeled Compounds (2)
By Research Areas:	Cancer (2) Infection (4) Metabolic Disease (1) Neurological Disease (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: SphK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N6719

Fumonisin B1 5+ Cited Publications	Acyltransferase	Infection
Fumonisin B1 is a mycotoxin produced from Fusarium moniliforme. Fumonisin B1 is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis. Fumonisin B1 is the most abundant and toxic fumonisin .

HY-134427

Palmitoyl coenzyme A lithium 2 Publications Verification Palmitoyl CoA lithium	Endogenous Metabolite	Metabolic Disease
Palmitoyl coenzyme A lithium is an acyl-CoA thioester that can be transported into the mitochondrial matrix via the carnitine shuttle system and is involved in β-oxidation. Palmitoyl coenzyme A lithium can also be used as a substrate for sphingosine biosynthesis .

HY-N6723

Fumonisin B2	Ceramidase Acyltransferase	Infection Cancer
Fumonisin B2 is a selective ceramide synthase inhibitor and carcinogenic mycotoxin with toxicity comparable to that of Fumonisin B1 (HY-N6719). Fumonisin B2 inhibits de novo sphingolipid biosynthesis by blocking the amide bond formation between fatty acids and dihydrosphingosine, which leads to a massive intracellular accumulation of free dihydrosphingosine, altered sphingosine levels, subsequent inhibition of cell proliferation, and induction of cell death. Fumonisin B2 is used to investigate the pathogenesis of diseases associated with Fusarium verticillioides contamination, including equine leukoencephalomalacia, porcine pulmonary edema syndrome, human esophageal cancer, and rat hepatocellular carcinoma .

HY-N6723S

Fumonisin B2-13C34	Isotope-Labeled Compounds	Infection
Fumonisin B2- ¹³C₃₄ is the ¹³C labeled Fumonisin B2 (HY-N6723) . Fumonisin B2, a mycotoxin produced by Fusarium moniliforme in various grains, is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis .

HY-N6719S

Fumonisin B1-13C34	Isotope-Labeled Compounds	Infection
Fumonisin B1- ¹³C₃₄ is the ¹³C labeled Fumonisin B1 (HY-N6719) . Fumonisin B1 is a mycotoxin produced from Fusarium moniliforme. Fumonisin B1 is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis. Fumonisin B1 is the most abundant and toxic fumonisin .

HY-148747

Ganglioside GD3 (d18:1/12:0)	Biochemical Assay Reagents	Neurological Disease Cancer
Ganglioside GD3 (d18:1/12:0) is a type of glycosphingolipid, the d18:1 indicates the sphingosine base, and the 12:0 represents the fatty acid part which is lauric acid. Ganglioside GD3 (d18:1/12:0) is a crucial intermediate in the biosynthesis pathway of gangliosides and is mainly found in the brain tissues of mammals. Ganglioside GD3 (d18:1/12:0) plays significant roles in development, cell signal transduction, and various diseases .

Cat. No.	Product Name	Type

HY-134427

Palmitoyl coenzyme A lithium 2 Publications Verification Palmitoyl CoA lithium	Biochemical Assay Reagents
Palmitoyl coenzyme A lithium is an acyl-CoA thioester that can be transported into the mitochondrial matrix via the carnitine shuttle system and is involved in β-oxidation. Palmitoyl coenzyme A lithium can also be used as a substrate for sphingosine biosynthesis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6719

Fumonisin B1 5+ Cited Publications	Infection Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Antibiotics Antibacterial Disease Research Endogenous metabolite Disease Research Fields Other Antibiotics Source Classification	Acyltransferase
Fumonisin B1 is a mycotoxin produced from Fusarium moniliforme. Fumonisin B1 is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis. Fumonisin B1 is the most abundant and toxic fumonisin .

HY-N6723

Fumonisin B2	Infection Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Antibiotics Antibacterial Disease Research Endogenous metabolite Disease Research Fields Other Antibiotics Source Classification	Ceramidase Acyltransferase
Fumonisin B2 is a selective ceramide synthase inhibitor and carcinogenic mycotoxin with toxicity comparable to that of Fumonisin B1 (HY-N6719). Fumonisin B2 inhibits de novo sphingolipid biosynthesis by blocking the amide bond formation between fatty acids and dihydrosphingosine, which leads to a massive intracellular accumulation of free dihydrosphingosine, altered sphingosine levels, subsequent inhibition of cell proliferation, and induction of cell death. Fumonisin B2 is used to investigate the pathogenesis of diseases associated with Fusarium verticillioides contamination, including equine leukoencephalomalacia, porcine pulmonary edema syndrome, human esophageal cancer, and rat hepatocellular carcinoma .

Cat. No.	Product Name	Chemical Structure

HY-N6723S

Fumonisin B2-13C34
Fumonisin B2- ¹³C₃₄ is the ¹³C labeled Fumonisin B2 (HY-N6723) . Fumonisin B2, a mycotoxin produced by Fusarium moniliforme in various grains, is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis .

HY-N6719S

Fumonisin B1-13C34
Fumonisin B1- ¹³C₃₄ is the ¹³C labeled Fumonisin B1 (HY-N6719) . Fumonisin B1 is a mycotoxin produced from Fusarium moniliforme. Fumonisin B1 is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis. Fumonisin B1 is the most abundant and toxic fumonisin .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy